Shahneen Sandhu
Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.
Overview
Shahneen Sandhu is a medical oncologist and Lead for Genitourinary Oncology Theranostics at the Peter MacCallum Cancer Centre in Melbourne. She runs the medical oncology side of Peter Mac's theranostics programme, leading combination trials such as PRINCE and UpFrontPSMA that pair lutetium-177 PSMA-617 with androgen receptor pathway inhibitors, chemotherapy and immunotherapy. Her publications include the UpFrontPSMA trial of sequential lutetium-177 PSMA-617 and docetaxel against docetaxel alone in metastatic hormone-sensitive prostate cancer. She also contributes to melanoma and early-phase research.
| Title | Journal | Year |
|---|---|---|
| Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in metastatic hormone-sensitive prostate cancer (UpFrontPSMA) | Lancet Oncology | 2024 |
Similar pages
not linked directly; found by shared links- PersonLouise Emmett
Shares 177Lu-PSMA-617 (Pluvicto) with olaparib, TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan.
- PersonMichael Hofman
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA.
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Adding a PARP inhibitor to PSMA radioligand therapy, 177Lu-PSMA-617 (Pluvicto) with olaparib, PSMA, Radioligand therapy (beta emitters).
- TrialTheraP (ANZUP 1603)
Shares Adding a checkpoint inhibitor to PSMA radioligand therapy, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer.
- PersonDeclan G. Murphy
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA, Prostate cancer.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.
- PersonMichael J. Morris
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.